Thomas Gad - 19 Sep 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
CHIEF BUSINESS OFFICER, Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
19 Sep 2024
Transactions value $
$100,000
Form type
4
Filing time
20 Sep 2024, 16:15:04 UTC
Previous filing
17 Sep 2024
Next filing
22 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Options Exercise $100K +22.8K +14.39% $4.38 182K 19 Sep 2024 Direct F1
holding YMAB Common Stock 67.7K 19 Sep 2024 By GAD Enterprises LLC F2
holding YMAB Common Stock 60K 19 Sep 2024 By Children F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Employee Stock Option (right to buy) Options Exercise $0 -22.8K -13.75% $0.00 143K 19 Sep 2024 Common Stock 22.8K $4.38 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired through the exercise of Employee Stock Options.
F2 Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
F3 Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.
F4 The option is fully vested and exercisable.